Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04921748
Other study ID # Neurorehab in PD
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 1, 2019
Est. completion date February 28, 2021

Study information

Verified date June 2021
Source IRCCS National Neurological Institute "C. Mondino" Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The sequence effect (SE), defined as a reduction in amplitude of repetitive movements, is a common clinical feature of Parkinson's disease (PD), being a major contributor to freezing of gait (FOG). During walking, SE manifests as a step-by-step reduction in step length when approaching a turn or gait destination (dSE). The investigators studied the effect of a 4-week rehabilitation program on the destination sequence effect in patients affected by Parkinson's disease with and without Freezing of Gait. All subjects were evaluated with inertial gait analysis for dSE recording.


Description:

Gait impairment and freezing of gait (FOG) represent common and disabling symptoms of Parkinson's disease (PD). The antiparkinsonian therapy positively modulates a subset of gait parameters, such as speed of gait and stride length, while its impact on FOG is limited. Growing evidence supports the efficacy of neurorehabilitation in the treatment of PD across all phases of the disease. In the last years, the advent of reliable wearable devices has prompted the widespread study of several parameters of the parkinsonian gait in both clinical and research settings. The sequence effect (SE), defined as a reduction in amplitude of repetitive movements, is a common clinical feature of several tasks of patients affected by PD, being identifiable in early as well as advanced stages of the disease. During walking, SE manifests as a step-by-step reduction in step length when approaching a turn or gait destination (destination sequence effect - dSE). SE is specifically pronounced in PD patients affected by FOG, and it arises immediately before a FOG episode induced by a turning or a dual-task. SE may be acutely modulated by several rehabilitative strategies such as split-belt treadmill and reinforcement of visual cues, but not by repetitive transcranial magnetic stimulation (rTMS), antiparkinsonian drugs administration, and attention strategies did not influence the SE, the evidence on the role of neurorehabilitation on gait SE improvement and retention is extremely scarce. The investigators plan to enroll 43 subjects according to sample size calculation. Patients will be divided into two groups: patients with freezing of gait (FOG) and without FOG. The subjects will be divided into two groups: 1) patients with freezing of gait (PD+FOG), or 2) patients without freezing of gait (PD-FOG). FOG phenotype is defined as: a score between 1 and 4 at either item "2.13 Freezing" or item "3.11 Freezing of gait" of the Unified Parkinson Disease Rating Scale (UPDRS). All patients will be treated with a standardized 4-week rehabilitation in-hospital program. At hospital admission (T0), patients who fulfill inclusion/exclusion criteria will be tested with instrumental gait analysis and administration of a set of the following clinical scales: rating of PD related motor disability with the Unified Parkinson's Disease Rating Scale - part III (UPDRS-III); rating of functional independence as measured through the Functional Independence Measure (FIM); and rating of dependence in activity of daily living according to Barthel Index. After that, patients will be treated with 90-minute daily rehabilitative sessions, 6 days a week (Monday through Saturday) for four weeks (passive, active-assisted, and active exercises, isotonic and isometric exercises for the major muscles of the limbs and trunk, cardiovascular warm-up exercises, muscle stretching exercises for functional purposes, balance training exercises, specific motor exercise for hypokinesia, and 45 minutes of overground gait training delivered without devices or cueing). The rehabilitation program will be the same in PD+FOG and PD-FOG groups. At the end of the rehabilitation program (T1), the patients will complete the study procedure with a second instrumental gait analysis evaluation and the administration of the same set of clinical scales. No modifications of the drug regimen were allowed during the study. The gait analysis will be performed with wearable, wireless, inertial system, secured to the back of the patients between L5 and S1 vertebrae. All subjects will be recorded in the morning (between 9:00 a.m. and 11:00 a.m.) and in the ON condition. The investigators plan to record a walk, at a comfortable pace, of 20 meters. The subjects will stop independently at the end of the 20-meter pathway, clearly marked by a straight line on the ground. Gait assessments with episodes of freezing of gait or pauses will be discrded. For each subject, three optimal performed gait assessments will be recorded. Regarding gait parameters the investigators will record: speed (m/s), cadence (steps/minute), stride length (meter), step length (meter), stride duration (second), single support, double support, swing duration, stance duration (percentage stride distribution). The destination Sequence Effect (dSE) will be computed as a regression slope (β) of step length according to a previously described and validated methodology where step length is plotted against step number. Briefly, the length of the last six steps ahead of the final stride are plotted against the step number, and the linear regression slope (β) will represent a measure of dSE. In addition, the intercept (I) of the regression curve will be used as an indirect measure of gait hypokinesia. For each group, the relationship between gait hypokinesia and sequence effect is expressed by the function of the linear regression as follow: y = β (x) + I.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date February 28, 2021
Est. primary completion date January 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Idiopathic Parkinson's disease - Hoehn and Yahr stage between I and IV - Mini-Mental State Examination score above 24. Exclusion Criteria: - Major psychiatric or other neurological conditions, - Rheumatological diseases - Ophthalmic diseases - Orthopedic diseases - Ongoing or previous treatment with neuroleptic drugs - Patients with deep brain stimulation - Any change in dose or regimen of the anti-parkinsonian therapy in the last month before enrolment.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Neurorehabilitation
All patients will be treated with an in-hospital rehabilitation program focused on the rehabilitation of gait disorder in PD with 90-minute daily sessions, 6 days a week (Monday through Saturday) for four weeks. The rehabilitation treatment includes passive, active-assisted, and active exercises, isotonic and isometric exercises for the major muscles of the limbs and trunk, cardiovascular warm-up exercises, muscle stretching exercises for functional purposes, balance training exercises, specific motor exercise for hypokinesia, and 45 minutes of overground gait training delivered without devices or cueing The rehabilitation program is the same in PD patients with and without FOG.

Locations

Country Name City State
Italy IRCCS Mondino Foundation Pavia

Sponsors (1)

Lead Sponsor Collaborator
IRCCS National Neurological Institute "C. Mondino" Foundation

Country where clinical trial is conducted

Italy, 

References & Publications (2)

Cao SS, Yuan XZ, Wang SH, Taximaimaiti R, Wang XP. Transverse Strips Instead of Wearable Laser Lights Alleviate the Sequence Effect Toward a Destination in Parkinson's Disease Patients With Freezing of Gait. Front Neurol. 2020 Aug 12;11:838. doi: 10.3389/fneur.2020.00838. eCollection 2020. — View Citation

Kang SY, Wasaka T, Shamim EA, Auh S, Ueki Y, Lopez GJ, Kida T, Jin SH, Dang N, Hallett M. Characteristics of the sequence effect in Parkinson's disease. Mov Disord. 2010 Oct 15;25(13):2148-55. doi: 10.1002/mds.23251. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Destination sequence effect (dSE) modifications Using an inertial gait analysis we will explore the modifications of destination sequence effect in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program Change from baseline (T0) to four weeks (T1)
Secondary Between-group comparison of dSE Comparison of destination Sequence Effect in PD patients with FOG vs. PD patients without FOG Baseline (T0)
Secondary Gait hypokinesia modifications Using an inertial gait analysis we will explore the modifications of intercept "I" in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program Change from baseline (T0) to four weeks (T1)
Secondary Speed modifications Using an inertial gait analysis we will explore the modifications of speed (m/s) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program Change from baseline (T0) to four weeks (T1)
Secondary Cadence modifications Using an inertial gait analysis we will explore the modifications of cadence (steps/min) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program Change from baseline (T0) to four weeks (T1)
Secondary Stride duration modifications Using an inertial gait analysis we will explore the modifications of stride duration (s) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program Change from baseline (T0) to four weeks (T1)
Secondary Stride lenght modifications Using an inertial gait analysis we will explore the modifications of stride length (m) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program Change from baseline (T0) to four weeks (T1)
Secondary Stance modifications Using an inertial gait analysis we will explore the modifications of stance phase (%) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program Change from baseline (T0) to four weeks (T1)
Secondary Swing modifications Using an inertial gait analysis we will explore the modifications of Swing phase (%) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program Change from baseline (T0) to four weeks (T1)
Secondary Double support modifications Using an inertial gait analysis we will explore the modifications of double support (%) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program Change from baseline (T0) to four weeks (T1)
Secondary Single support modifications Using an inertial gait analysis we will explore the modifications of single support (%) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program Change from baseline (T0) to four weeks (T1)
Secondary Motor disability improvement We will explore the changes in motor disability as measured by Unified Parkinson Disease Rating Scale - part III (UPDRS-III) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program Change from baseline (T0) to four weeks (T1)
Secondary Functional Independence improvement We will explore the changes in functional independence as measured by Functional Independence Measure (FIM) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program Change from baseline (T0) to four weeks (T1)
Secondary Dependence in activity of daily living improvement We will explore the changes in dependence in activity of daily living as measured by barthel Index in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program Change from baseline (T0) to four weeks (T1)
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Recruiting NCT04788693 - Effects of Gait Rehabilitation With Motor Imagery in People With Parkinson's Disease N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A